RxDoctor Payments Data

Lawrence Littell, DO

Pain Medicine · Watertown, NYNPI 1295792893

Payments from drug & device makers

$1,516in general payments, 2019–2025

Across 94 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$568
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$508
  • AbbVie$192
  • Takeda Pharmaceuticals U.S.A., Inc.$58
  • Neurocrine Biosciences, Inc.$49
  • Johnson & Johnson$35
  • plus $106 from 4 others

What the payments were for

  • Food & beverage$1,46997%
  • Education$473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,516 in reported general payments places this provider in the 45th percentile of 503 pain medicine providers in New York.

See all pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$10,391
Medicare patients
46
Services billed
136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole31$45,673
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen433$24,851
MovantikNaloxegol Oxalate33$13,229
Oxymorphone Hcl ErOxymorphone Hcl17$13,197
TrintellixVortioxetine Hydrobromide19$8,868
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine236$8,566
LinzessLinaclotide12$6,245
Lisdexamfetamine Dimesylate21$4,959
VyvanseLisdexamfetamine Dimesylate11$4,035
Baclofen194$3,792
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl14$3,487
Vilazodone Hcl36$3,374
Asenapine Maleate12$3,137
Carisoprodol143$2,235
Lurasidone Hcl23$2,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$58$12,90330 claims
AbbVieLinzess$192$6,24512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 503 pain medicine providers in New York.

Other pain medicine in Watertown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →